Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul G Corn

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate CancerWei Zhang, Bo Liu, Wenhui Wu, et al.
Molecular Cancer Therapeutics|June 23, 2021
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate CancerCheng Wu, Shan Peng, Patrick G Pilié, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2020
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate CancerPaul G Corn, Miao Zhang, Graciela M Nogueras-Gonzalez, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2024
Body composition as a determinant of the therapeutic index with androgen signaling inhibitionAndrew W Hahn, Rebecca S Tidwell, Patrick G Pilie, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Science Translational Medicine|September 5, 2014
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesXinhai Wan, Paul G Corn, Jun Yang, et al.
Science Signaling|May 22, 2014
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancerLikun Li, Wenjun Chang, Guang Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate CancerWei Zhang, Bo Liu, Wenhui Wu, et al.
Molecular Cancer Therapeutics|June 23, 2021
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate CancerCheng Wu, Shan Peng, Patrick G Pilié, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2020
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate CancerPaul G Corn, Miao Zhang, Graciela M Nogueras-Gonzalez, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)Bilal A Siddiqui, Brian F Chapin, Sonali Jindal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2012
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialDavid C Smith, Matthew R Smith, Christopher Sweeney, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2024
Body composition as a determinant of the therapeutic index with androgen signaling inhibitionAndrew W Hahn, Rebecca S Tidwell, Patrick G Pilie, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Science Translational Medicine|September 5, 2014
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastasesXinhai Wan, Paul G Corn, Jun Yang, et al.
Science Signaling|May 22, 2014
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancerLikun Li, Wenjun Chang, Guang Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
Pageof 10